Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Growth Factors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06120140
What this trial is testing

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 305
Large-scale testing (Phase 3)Active Not RecruitingNCT05607550
What this trial is testing

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Who this might be right for
Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung CancerEGFR Exon 20 Mutations
ArriVent BioPharma, Inc. 398
Post-approval studies (Phase 4)Study completedNCT07684625
What this trial is testing

THE EFFECT OF LUMBRICUS RUBELLUS DLBS1033 EXTRACT IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Who this might be right for
Diabetes Mellitus, Type 2
Universitas Sebelas Maret 60
Large-scale testing (Phase 3)Study completedNCT01908426
What this trial is testing

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Who this might be right for
Hepatocellular Carcinoma
Exelixis 707
Early research (Phase 1)Study completedNCT00551850
What this trial is testing

A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients

Who this might be right for
Advanced CancerRefractory Cancer
AVEO Pharmaceuticals, Inc. 37
Early research (Phase 1)Study completedNCT02228369
What this trial is testing

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

Who this might be right for
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
AstraZeneca 108
Early research (Phase 1)Ended earlyNCT01004822
What this trial is testing

A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Pfizer 31
Post-approval studies (Phase 4)Study completedNCT03853551
What this trial is testing

Osimertinib Study in Indian Patients

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Early research (Phase 1)Study completedNCT03834662
What this trial is testing

A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies

Who this might be right for
Malignant Solid Tumor
Bristol-Myers Squibb 19
Testing effectiveness (Phase 2)Looking for participantsNCT07278661
What this trial is testing

Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery.

Who this might be right for
Chirurgical InterventionThrombocytopaenia
Nantes University Hospital 136
Not applicableEnrolling By InvitationNCT07015554
What this trial is testing

Serum IGF1 on Female HFpEF Patients

Who this might be right for
HFpEF - Heart Failure With Preserved Ejection Fraction
The University of Hong Kong-Shenzhen Hospital 120
Very early researchWithdrawnNCT02695641
What this trial is testing

Reduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis Patients

Who this might be right for
End Stage Renal DiseaseHemodialysis Vascular Access Failure
Mayo Clinic
Early research (Phase 1)Active Not RecruitingNCT05222802
What this trial is testing

Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)

Who this might be right for
Glioblastoma Multiforme
Katmai Pharmaceuticals Inc. 52
Not applicableUnknownNCT05700136
What this trial is testing

Factors Associated With Infant Circadian Rhythm, Growth, and Temperament

Who this might be right for
Circadian Rhythm Sleep Disorder, Jet Lag Type
UCSI University 216
Large-scale testing (Phase 3)Study completedNCT01774721
What this trial is testing

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Who this might be right for
Non-small Cell Lung Cancer With EGFR-Activating Mutations
Pfizer 452
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05982275
What this trial is testing

Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant

Who this might be right for
Multiple MyelomaAllogeneic Stem Cell Transplantation
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 25
Not applicableUnknownNCT01850628
What this trial is testing

NSABP Biospecimen Discovery Project

Who this might be right for
Breast Cancer
NSABP Foundation Inc 50
Large-scale testing (Phase 3)Study completedNCT01935492
What this trial is testing

8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of BreastMetastatic Breast Cancer
Borstkanker Onderzoek Groep 420
Post-approval studies (Phase 4)Study completedNCT03590444
What this trial is testing

Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser

Who this might be right for
Diabetic Retinal Edema
Hospital Hietzing 50
Early research (Phase 1)Study completedNCT04187898
What this trial is testing

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

Who this might be right for
NeutropeniaBreast Cancer
Spectrum Pharmaceuticals, Inc 59
Next Page